-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 23, 2021, Poxel and Sumitomo Dainippon Pharma jointly announced that its "first-in-class" diabetes innovative drug Twymeeg (imeglimin hydrochloride) oral tablet application was approved in Japan for treatment Type 2 diabetes
Twymeeg has a unique hypoglycemic mechanism, which provides a new treatment option for patients in all stages of type 2 diabetes.
Previously, researchers carried out a TIMES clinical project in Japan that included three key Phase 3 trials, and all trials met the primary endpoint
Type 2 diabetes is a chronic metabolic disease that affects more than 200 million patients worldwide
Note: The original text has been deleted
Reference materials:
[1] Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan.